Compare iShares International Treasury Bond ETF (IGOV) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Organon & Co. Common Stock — how do they compare? iShares International Treasury Bond ETF trades at $39.67 (market cap $1.31B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 2.8× iShares International Treasury Bond ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Organon & Co. Common Stock for 0 Days on average.
| IGOV | OGN | |
|---|---|---|
Market Cap | $1.31B | $3.61B |
Volume | 69,817 | 1,808,049 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $13.81 |
52-Week Low | $39.58 | $5.70 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | — | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.79, up 0.53% with mixed technical signals showing bearish moving averages but bullish oscillators. The stock faces resistance at $40-$42 while finding support near $39. Financial ratios remain unavailable, requiring deeper fundamental analysis to assess valuation and profitability metrics.
The stock's outlook remains uncertain with technical indicators conflicting and limited fundamental data available. Rising bond yields create macroeconomic headwinds for equities, though inverse Treasury ETF opportunities mentioned in recent news could signal defensive positioning. Investors need updated financial disclosures to properly evaluate investment merit.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
